• LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients
• Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer
• As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients

Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy.

Specifically, Liora has created the LiGHT System, which is believed to provide many advantages over other proton therapy methods and systems that are currently available. While it is smaller in size, the system can be deployed quickly and is much more cost-effective to build and use. 

The system also eliminates mechanical energy degraders, reduces proton loss and enables more efficiency as it adjusts energy electronically. It also allows for much more precise dosing and lets you change energy levels much faster than many other methods.

The LiGHT system synergizes incredibly well with LIXTE’s lead clinical candidate and main product, LB-100, a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”) that boosts the activity and effectiveness of chemotherapy and immunotherapy. It has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by more than two dozen published preclinical and translational studies. The compound is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.

Together, the companies, and their flagship products and systems, are building a new cancer care ecosystem. Specifically, Liora’s radiotherapy technology complements LIXTE’s LB-100 approach.

The LiGHT System works to effectively destroy cancer cells by precisely delivering the right amount of radiation in the right spots. This synergizes well with LB-100, as the compound not only makes cancer cells more vulnerable to the radiation, but also helps to prevent these cancer cells from being able to repair themselves after being damaged.

Simply put, the LB-100 may weaken the cancer cells, thus boosting how well the radiation from the LiGHT System is able to damage them, while also preventing the cells from being able to recover after being damaged by the radiation.

As a result, the pair has the potential to become a multi-modal cancer care platform that helps patients enjoy more effective cancer treatments. The acquisition allows LIXTE to test the drug-device combo in trials and see just how much more effective and efficient the ecosystem may be than other currently available methods.

About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing cancer therapies built around a novel biological target. Instead of introducing standalone treatments, the company is focused on enhancing the effectiveness of established cancer therapies and addressing challenges that limit outcomes in oncology.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

• Appointment of fusion researcher Fabrice David adds scientific oversight as commercialization plans advance.
• Travis Yakimishyn joins as Chief Electrical & Power Systems Officer to lead utility-scale integration.
• The company is transitioning to American Fusion Inc. following its merger with Kepler Fusion Technologies, with filing and audits nearing completion as the company prepares for SEC reporting status.
• Management reiterates goal of deploying a 100-megawatt operational unit by year-end 2026, with Kepler‘s plan to sell electricity on a per-kilowatt basis to utilities and industrial customers.

Renewal Fuels (OTC: RNWF) (d/b/a American Fusion), an advanced energy platform company focused on the development and commercialization of fusion energy technologies, is working to advance its Texatron(TM) aneutronic fusion system, while simultaneously strengthening governance, engineering leadership and regulatory positioning.

In February, the company appointed Fabrice David as an independent director (https://ibn.fm/yJaLP). David is described as a scientific researcher and inventor with more than 130 publications and multiple patents spanning advanced energy systems and experimental physics. As an Independent Director, David will provide scientific and technical oversight, insight into intellectual property strategy, and independent judgment supporting disciplined governance as the company advances its Texatron platform.

Chief Executive Brent Nelson said in a statement that David’s background in fusion-adjacent research, intellectual property development and scientific governance aligns with the company’s transition toward commercialization. “His experience across experimental validation, intellectual property development, and international scientific collaboration strengthens our Board as we continue building a scalable fusion energy platform,” Nelson said.

Richard Hawkins, Chairman and CEO of Renewal Fuels, Inc., added that David’s background reflects decades of disciplined research and intellectual rigor across fusion-adjacent systems and advanced energy technologies. “His perspective supports our commitment to long-term value creation, strong governance, and responsible innovation.”

Independent oversight is particularly relevant in fusion, where technical claims often precede commercial validation. American Fusion is still in the development phase. The company reports stable plasma formation at sub-fusion temperatures using a proprietary pulsed torsatron configuration and deuterium–helium-3 fuel, but it has not demonstrated net-energy gain.

Alongside the board appointment, the company named Travis Yakimishyn as Chief Electrical & Power Systems Officer (https://ibn.fm/PZRYy). Yakimishyn is a licensed professional engineer with experience in high-voltage systems, substations and grid interconnection planning.

In his role, Yakimishyn will oversee the electrical architecture and grid integration strategy for Kepler’s Texatron platform. His responsibilities include advancing scalable electrical design standards, coordinating interconnection pathways, aligning protection and control systems with commercial deployment requirements, and ensuring that the company’s power systems infrastructure is engineered for long-term operational stability.

Nelson said Yakimishyn’s role in bridging plasma physics and utility-scale electrical engineering has been instrumental. “His deep expertise in high-voltage systems and infrastructure deployment significantly strengthens our ability to transition Texatron(TM) from advanced development into commercial operation.”

In a follow-up interview, Nelson and Kepler Chief Technology Officer Dr. John E. Brandenburg outlined a 2026 roadmap centered on delivering a 100-megawatt fusion power unit (https://ibn.fm/4bddO).

Nelson said component integration and subsystem validation are progressing toward full-scale assembly. He emphasized that Kepler’s platform is compatible with existing grid infrastructure, noting that capacitor banks, transformers, and inverters used in solar and wind installations are directly adaptable to Kepler’s system.

“Our engineering milestones continue to align with our deployment schedule,” Nelson said. “We’re now moving from proof-of-concept validation into full-scale assembly and integration. Every step reinforces our confidence that our first 100-megawatt unit will be grid-ready in partnership with our North Texas utility collaborators.”

The company’s commercial model centers on power-as-a-service. Rather than licensing reactor designs, Kepler intends to sell electricity on a per-kilowatt basis at pricing it says is competitive with hydropower and other baseload sources.

Nelson described a developing pipeline that includes utilities, industrial operators and remote communities seeking continuous, emission-free generation. “We’re seeing strong demand across multiple sectors,” Nelson noted. “Industrial customers want predictable, low-cost power. Remote communities want reliability without high maintenance. And utilities want scalable, dispatchable clean energy. Our model delivers all three while maintaining compelling margins.”

Discussions have also involved government entities, including the Department of Defense and NASA, for multiple applications ranging from military microgrids to lunar surface power concepts to resilient infrastructure for remote or disaster-prone regions.

The company’s broader corporate structure is also evolving. Renewal Fuels has filed a corporate action with FINRA to formally change its legal name to American Fusion Inc. The company said its Form 10 registration statement under the Securities Exchange Act of 1934 is substantially complete, with EDGAR access pending. A PCAOB audit covering fiscal 2024 and 2025 is nearing completion. Achieving SEC reporting status would move the company into a more transparent regulatory framework, potentially widening its investor base.

The company’s recent appointments suggest an effort to add technical depth and governance discipline before approaching large-scale infrastructure investors. Nelson reiterated the company’s belief that the Texatron platform is a high-value opportunity for investors, offering an attractive blend of competitive pricing, broad applicability, and the absence of radioactive waste or long-term environmental liabilities.

“We’re building a platform that can scale globally,” Nelson said. “Our technology is designed for rapid deployment, minimal maintenance, and seamless integration with existing grid assets. We believe this positions Kepler to become one of the most impactful clean-energy providers of the next decade.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to RNWF are available in the company’s newsroom at https://ibn.fm/RNWF

• “The EMA’s positive opinion signifies an important step for Soligenix as we continue to advance the program,” says company CEO.
• The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval.
• Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright.

For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a drug’s scientific rationale but can also unlock development incentives that accelerate its path forward. In that context, Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need, announced that it has received a positive opinion from the EMA’s Committee for Orphan Medicinal Products for its pipeline product dusquetide in the treatment of Behcet’s disease.

“We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program,” said Soligenix CEO and president Christopher J. Schaber, PhD. Behçet’s disease is an area of unmet medical need, with up to 18,000 people in the U.S., 50,000 people in Europe, 350,000 people in Türkiye and as many as 1 million people worldwide affected by this incurable disease.

“Given the clinically meaningful improvements seen in our phase 2 proof-of-concept study in patients with oral aphthous ulcers due to Behçet’s disease, we are hopeful dusquetide will have a role to play in helping underserved patients suffering from this difficult to treat and chronic auto-immune disease,” Schaber continued. “The EMA’s positive opinion signifies an important step for Soligenix as we continue to advance the program and adds significantly to the existing intellectual property estate surrounding this novel technology.”

In the European Union, orphan medicinal product designation is granted to therapies intended to treat life-threatening or chronically debilitating conditions affecting no more than five in 10,000 people, according to the European Commission. The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval, as outlined by the European Medicines Agency. These benefits are designed to encourage companies to invest in treatments for rare diseases that might otherwise lack sufficient commercial incentive.

Behcet’s disease is a rare, chronic, multisystem inflammatory disorder characterized by recurrent oral and genital ulcers, skin lesions and, in some cases, inflammation affecting the eyes, joints, blood vessels and nervous system. The National Library of Medicine describes Behcet’s as a complex autoimmune-related condition that can lead to serious complications, including vision loss when ocular inflammation is severe. While the disease is more common along the historic Silk Road regions such as Türkiye and parts of the Middle East and East Asia, it remains rare in Europe and North America, supporting its qualification for orphan designation under EU criteria.

There is currently no cure for Behcet’s disease. Treatment generally focuses on reducing inflammation and managing symptoms through corticosteroids, immunosuppressive medications and biologic agents. Because the disease can relapse unpredictably and may require long-term immunosuppressive therapy, patients often face ongoing risks associated with chronic immune modulation. This underscores the importance of developing novel approaches that aim to regulate immune responses more precisely rather than broadly suppress them.

Soligenix’s investigational therapy for Behcet’s disease is dusquetide, the active pharmaceutical ingredient in SGX945. According to the company, dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright. Dusquetide targets the p62/sequestosome-1 signaling pathway, which plays a role in regulating inflammation and immune responses. By modulating this pathway, dusquetide is intended to reduce inflammatory damage while preserving normal immune defense mechanisms.

Soligenix has previously evaluated dusquetide in other inflammatory settings. The company reports that dusquetide has been studied in clinical trials for oral mucositis and other immune-related conditions, providing clinical experience with the molecule’s safety and mechanism of action. The rationale for its use in Behcet’s disease stems from its potential ability to rebalance dysregulated immune responses that drive ulcer formation and systemic inflammation.

The positive opinion from the Committee for Orphan Medicinal Products does not itself constitute marketing approval, but it is a critical regulatory milestone. Following a positive opinion, the European Commission often issues a formal decision on orphan designation. If granted, the designation may provide Soligenix with development incentives and regulatory support that could facilitate further clinical advancement.

For patients living with Behcet’s disease, the potential availability of a new therapeutic option that aims to regulate immune response rather than broadly suppress it could represent a meaningful advancement. Chronic inflammation and recurrent ulcerations can significantly impair quality of life, and current therapies may not fully control disease activity or may carry long-term safety considerations. The advancement of dusquetide under an orphan designation framework signals continued momentum in rare disease research.

As Soligenix moves forward, the European Medicines Agency’s positive opinion provides both validation and strategic leverage. In rare-disease drug development, regulatory alignment and incentive programs can make a substantial difference in the feasibility of bringing new treatments to market. For Soligenix, this milestone reinforces its commitment to addressing rare inflammatory disorders and strengthens the foundation for continued development of dusquetide in Behcet’s disease.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions.
• HeartBeam’s strategy is built around addressing a long-standing gap in cardiac care.
• Looking forward, HeartBeam is focused on advancing both its hardware and software platforms.

HeartBeam (NASDAQ: BEAT) stands at a pivotal point in its development as a medical technology company focused on transforming how cardiac arrhythmias are detected, evaluated and monitored. Headquartered in Santa Clara, California, HeartBeam is building a platform designed starting with its FDA-cleared synthesized 12-lead ECG system to bring clinically meaningful ECG data out of traditional healthcare facilities and into more accessible, patient-centered settings.

The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions. Those signals are then synthesized into a 12-lead ECG using a personalized transformation matrix. This unique approach delivers exceptional data fidelity through a portable device that can be used by patients wherever they are when arrhythmia symptoms occur – without being in a healthcare facility, the currently cleared indications for use.

HeartBeam’s strategy is built around addressing a long-standing gap in cardiac monitoring. Conventional 12-lead ECG systems, which are the clinical standard for evaluating arrhythmias and ischemic events, require wired electrodes, trained personnel and clinical infrastructure. At the same time, most consumer and portable ECG devices rely on single-lead or low-resolution signal capture, which limits their utility.

HeartBeam’s technology is designed to bridge this gap by combining portability with clinical-grade signal quality. In the near term, HeartBeam is focusing on bringing its technology to market through a limited launch in early 2026, following FDA clearance for the company’s 12-lead ECG synthesis software for arrhythmia assessment in December 2025.

Looking forward, HeartBeam is focused on advancing both its hardware and software platforms. The company’s proprietary system integrates embedded electrodes into a handheld, credit card-sized device, allowing patients to record cardiac signals without cables or external electrodes. In addition, the company has developed a working prototype of a 12-lead ECG extended wear patch monitor, which has the potential to be a best-in-class offering in an established multi-billion-dollar market with reimbursement.

In parallel with its hardware development, HeartBeam is pursuing a heart attack detection indication approval from FDA in the near future. According to the U.S. Centers for Disease Control and Prevention, heart disease continues to be the leading cause of death in the United States, responsible for roughly one in every five deaths each year. The company has already generated compelling proof-of-concept data and plans to generate additional clinical evidence to support the FDA submission.

The company is also building advanced analytical software designed to interpret the complex electrical data generated by the system. HeartBeam’s AI-based analysis tools are intended to help clinicians compare recordings to patient-specific baselines, identify clinically meaningful changes, and support faster decision-making. This integration of hardware and software reflects a broader digital health trend in which diagnostics, data analytics and remote monitoring are converging into unified platforms rather than standalone devices. The company plans to submit for FDA clearance of its AI-driven algorithms in the future.

The company’s broader vision remains centered on decentralizing cardiac detection. Most cardiac events occur outside clinical settings, and delays in obtaining meaningful ECG data can lead to missed diagnoses, unnecessary emergency visits and delayed treatment. HeartBeam’s technology is intended to reduce these gaps by enabling patients to capture clinically relevant data at the moment symptoms occur, while allowing clinicians to review and interpret that data remotely. This model aligns with the continued expansion of telehealth, remote patient monitoring and home-based care across healthcare systems.

In addition to the limited launch of its FDA cleared technology in early 2026, HeartBeam’s progress also reflects a long-term growth strategy looking to capture significant unmet need. The company continues to invest in regulatory alignment, technical validation and system integration as foundational steps toward broader market adoption. Its groundbreaking 3D ECG approach, cable-free hardware design and future AI-driven analysis positions it within a differentiated niche of the cardiac care market, one focused on portability without sacrificing clinical precision.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Frontieras’ patent portfolio includes protection across five continents and nine countries, covering approximately 85% of global coal production.
• The FASForm(TM) process is designed as a closed-loop, zero-waste system that converts coal into multiple market-ready energy and industrial products.
• Long-term feedstock and product offtake frameworks are in place for the company’s flagship commercial facility.
• The Mason County project is structured as a large-scale infrastructure development with established engineering, construction, operations, logistics, and insurance partners.
• Frontieras’ commercialization strategy focuses on replicable facilities serving established energy and chemicals markets with existing demand.

Frontieras North America is an energy and environmental technology company focused on redefining how coal and other solid hydrocarbons are utilized within modern energy and industrial systems. Rather than treating coal as a fuel to be burned, the company applies patented processing technology to reform solid hydrocarbons into multiple market-ready energy and industrial products designed for existing global markets.

The company’s approach is rooted in extracting greater value from abundant natural resources through industrial innovation, addressing inefficiencies historically associated with conventional coal use. By separating coal into gases, liquids, and purified solid carbon, Frontieras positions coal as a versatile feedstock capable of supporting transportation, manufacturing, agriculture, and industrial infrastructure demand.

Frontieras emphasizes closed-loop, zero-waste processing as a means of producing energy products more efficiently while reducing emissions and unused byproducts.

Products and Projects

Frontieras’ core platform is FASForm(TM), a patented Solid Carbon Fractionation process that deconstructs coal by extracting volatiles, moisture, and contaminants. The process produces hydrogen, methane, naphtha, diesel, aviation fuel, and FASCarbon(TM), a low-sulfur technical carbon product.

The company is developing its first commercial-scale FASForm(TM) facility in Mason County, West Virginia, an estimated $850 million project designed to process approximately 7,500 tons of coal per day, or about 2.7 million tons annually. The facility is supported by a 10-year feedstock MOU using Pittsburgh #8 coal and a 10-year offtake LOI covering 100% of produced fuels, FASCarbon(TM), sulfuric acid, and fertilizer.

Engineering, construction, operations, logistics, and insurance partners are under executed agreements, and the project has completed FEL 1 and FEL 2, with substantial FEL 3 underway. Following its initial Mason County development, Frontieras plans to deploy additional FASForm(TM) facilities in West Virginia, Texas, and Wyoming, with longer-term international deployment in markets where its patent portfolio is in force.

Market Opportunity

Frontieras targets established global energy and chemicals markets with a combined estimated value exceeding $2.1 trillion. The company’s product portfolio aligns with large, existing demand across diesel, hydrogen, naphtha, jet fuel, technical carbon – coke, industrial chemicals, and fertilizer markets. These products are core industrial inputs with long-established supply chains, entrenched end-use applications, and global pricing benchmarks, reducing reliance on the creation of new or speculative markets.

These markets serve essential roles across transportation, agriculture, industrial machinery, aviation, steel manufacturing, petrochemicals, and food production, supporting continuous demand driven by infrastructure, manufacturing, and population growth. The planned design capacity of the first FASForm(TM) facility is approximately 7,500 tons per day, or about 2.7 million tons annually — equivalent to roughly 0.5% of current U.S. coal production. This design framework is intended to enable Frontieras to scale output incrementally while remaining aligned with existing market capacity, logistics networks, and demand profiles.

Leadership Team

Matthew McKean, Co-Founder & Chief Executive Officer, leads Frontieras’ overall strategy and execution and brings more than 25 years of experience across finance, operations, and business leadership. He previously co-founded a mortgage banking firm that grew into one of the largest originators in the southwestern U.S. before a successful exit, followed by senior leadership roles within large real estate finance organizations. McKean has been an active member of the CEO mentoring organization Vistage, advising companies across construction, finance, infrastructure, and consumer sectors. He holds a Bachelor of Science in Human Nutrition with an emphasis in Chemistry from Arizona State University and completed pre-med coursework.

Joseph Witherspoon, P.E., Co-Founder & Chief Technology Officer, is the inventor of the FASForm(TM) process and the author of the company’s core patents. He brings extensive experience in petroleum refining, natural gas processing, and chemical engineering from senior roles at Chevron, Enterprise Products, Sinclair Oil, and Marathon Petroleum. As a Process Design Engineer and Major Capital Project Manager, Witherspoon has led projects delivering significant operational and economic improvements. He holds a Bachelor of Science in Chemical and Fuels Engineering from the University of Utah and is a licensed Professional Engineer.

Andrea Moran, Chief Commercial Officer, oversees Frontieras’ commercialization strategy, capital formation, and go-to-market execution. She brings more than 25 years of experience in operations, management, and business development across the energy and infrastructure sectors. Prior to Frontieras, Moran served as Co-Founder and Vice President of Business Development at Yield Power Group, a project finance firm supporting energy and infrastructure projects ranging from $100 million to over $1 billion. She holds a Bachelor of Science in Political Science from the University of Wisconsin and serves on philanthropic and advisory boards.

José López, Chief Financial Officer, leads Frontieras’ financial strategy, operations, and capital planning. He brings over 20 years of experience in global finance and accounting, including senior roles at multinational public companies. López began his career at PwC’s external assurance practice, working across Houston, London, and The Hague. His background includes SEC reporting, corporate governance, FP&A, mergers and acquisitions, and capital markets transactions. He holds a Bachelor of Science in Accounting and Finance from the University of Houston–Clear Lake and is a licensed Certified Public Accountant.

For more information, visit the company’s website at www.Frontieras.com.

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties, announced the filing of an amended offering document for its brokered LIFE offering
• The amendment includes Quebec, site of the company’s rapidly developing Montauban Project, as an offering jurisdiction, with terms remaining the same as previously announced
• The offering looks to raise gross proceeds of up to C$7,000,600 from the sale of up to 10,295,000 units of the company at C$0.68 a unit
• ESGold has also engaged AXINO Capital to offer marketing services in Europe as part of its European marketing outreach

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, announced the filing of an amended offering document for its initial brokered LIFE offering. The amendment includes Quebec as an offering jurisdiction, with the terms of the offering remaining the same as previously announced on February 19, 2026 (https://ibn.fm/7AjB4). The offering, brokered by Red Cloud Securities, is to raise gross proceeds of up to C$7,00,600 from the sale of up to 10,295,000 units of the company at C$0.68 a unit.

The company intends to use the net proceeds from the sale of its units to advance its flagship Montauban Project in Quebec. Proceeds will also go into general working capital and corporate purposes (https://ibn.fm/Ik4Ho).

The Montauban property has a rich mining history dating back to the 1910s (https://ibn.fm/N5Ogh). Its legacy presents a unique opportunity for ESGold to transform legacy tailings into valuable resources through modern milling techniques while restoring the environment. Proceeds from the LIFE offering will go a long way in realizing the property’s true potential, while unlocking future value through ongoing exploration and development. 

In addition, ESGold has now engaged AXINO Capital GmbH, a privately owned full-service marketing firm based in Esslingen, Germany, to offer marketing services in Europe as part of its European market outreach. AXINO Capital will help ESGold distribute news and updates, further increasing investor awareness among institutional and retail audiences. More specifically, it will help strengthen ESGold’s visibility within German-speaking financial communities (https://ibn.fm/qz2YN).

The engagement is set to run for an initial term of twelve months, commencing March 1, 2026. It will be subject to applicable exchange policies and regulatory requirements, and is timely given ESGold’s advancements on its fully permitted Montauban Gold-Silver project that is set for production in 2026.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• AI data centers are rapidly increasing electricity consumption, creating new and significant pressures on America’s power infrastructure, with analysts warning that reliable electricity supply could become a defining constraint in global AI competition.
• Large AI facilities require integrated control of multiple energy assets and market inputs, with real-time monitoring and analytics becoming essential to the management of complex energy systems supporting AI infrastructure.
• GridAI is developing software to coordinate grid power, on-site generation, battery storage and backup systems for AI data-center campuses.

Artificial intelligence has triggered a global race for computing capacity, but a serious bottleneck is beginning to emerge: electricity. For companies building and operating AI infrastructure, access to reliable power is becoming as critical as access to advanced semiconductors. That shift is creating opportunities for GridAI Technologies (NASDAQ: GRDX), a technology company focused on intelligent energy orchestration.

GridAI is advancing a real-time software platform designed to orchestrate power systems serving hyperscale AI data-center campuses. The platform coordinates multiple energy inputs, covering grid electricity, on-site generation, battery energy storage systems and backup infrastructure, while also managing dynamic energy demand across large computing facilities.

The approach reflects a broader structural change in the AI economy: computing infrastructure is becoming tightly linked with energy infrastructure. A recent report highlighted the scale of the challenge. According to analysis cited by Goldman Sachs, data centers already consume roughly 6% of total U.S. electricity demand and that share could rise to about 11% by 2030 (https://ibn.fm/QpUa6). In other words, the next phase of the AI race may depend less on chips and more on the availability of large, stable power supplies.

This trend has strategic implications. While the United States currently leads global data-center capacity, analysts note that spare power generation margins in parts of the country are already tightening. Peak summer reserve capacity has fallen from about 26% five years ago to roughly 19% today, and could drop below 15% if demand continues to accelerate.

Against that backdrop, companies developing tools to manage electricity flows, generation assets and power markets are becoming increasingly relevant. GridAI’s technology sits at this intersection between digital infrastructure and energy systems. Rather than operating inside the data center at the computing level, the company focuses on the broader energy environment surrounding large AI facilities.

GridAI’s platform orchestrates external energy assets such as reciprocating engines, battery storage systems and renewable generation, while accounting for variables such as grid availability, natural gas prices, and electricity market conditions.

This orchestration layer is designed to help operators decide when to draw power from the grid, dispatch on-site generation or store energy in batteries. In some cases, these decisions are influenced by electricity market signals such as day-ahead or real-time pricing. The result is a software-driven approach to energy management that is exemplifies the rise of “energy intelligence platforms.”

These platforms collect operational data from power assets, analyze it in real time, and generate actionable insights for operators. They typically include features such as monitoring energy generation, integrating multiple energy systems, visualizing operational data and generating alerts that support faster decision-making.

The emergence of such platforms reflects a broader transformation in the energy sector itself. According to analysis from S&P Global, artificial intelligence is increasingly being used to manage large and complex energy systems (https://ibn.fm/YotW1).

Applications range from improving operational efficiency at individual assets to optimizing entire power networks and accelerating the development of new energy technologies. In practice, this means that electricity grids and power infrastructure are gradually evolving into data-driven platforms.

Utilities, energy developers and large industrial users are beginning to rely on advanced analytics and machine-learning tools to forecast demand, manage renewable generation and coordinate increasingly distributed power resources. For AI data centers, the stakes are particularly high.

Hyperscale computing campuses often require hundreds of megawatts of continuous electricity supply. Building sufficient grid infrastructure to meet that demand can take years due to permitting, equipment shortages and transmission constraints. In some cases, operators are turning to hybrid energy systems that combine grid electricity with on-site generation, battery storage and renewable power. Managing these systems efficiently is a complex operational challenge. Software platforms capable of coordinating multiple energy sources, while reacting to changing electricity prices, fuel costs and grid conditions, are becoming essential components of the infrastructure stack.

GridAI’s platform is designed to coordinate energy resources not only for AI campuses but also for distributed power systems more broadly, including fleets of energy assets and residential energy devices located behind the meter. Such systems are increasingly in demand as renewable energy, battery storage, and electrified technologies spread across power networks.

Industry forecasts suggest that the global need for new electricity capacity associated with AI data centers, electric vehicles, and other electrification, could exceed 50 gigawatts by 2028. Meeting that demand will require not only new generation and grid infrastructure, but also software capable of coordinating increasingly complex power systems. In that sense, the expansion of AI may depend as much on energy intelligence platforms as on computing power itself.

Companies developing software to manage these energy ecosystems, including firms like GridAI, are positioning themselves within a market that sits at the crossroads of two industries undergoing rapid transformation: artificial intelligence and electricity.

For more information, visit the company’s website at www.Grid-AI.com.

NOTE TO INVESTORS: The latest news and updates relating to GRDX are available in the company’s newsroom at https://ibn.fm/GRDX

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTC: SPAIF) and may include paid advertising.

• Canada has launched its first Defense Industrial Strategy, unlocking $180 billion in procurement opportunities over 10 years
• The strategy prioritizes domestic innovation in artificial intelligence, aerospace, and digital technologies
• Sparc AI’s patented spatial targeting technology and Overwatch navigation platform align with rising demand for advanced software-defined defense systems

Sparc AI (CSE: SPAI) (OTC: SPAIF) operates at the nexus of sensor technology, artificial intelligence, and next-generation target acquisition systems, a convergence increasingly integral to modern defense strategy. As global security dynamics shift and allied nations increase sovereign defense investment, the firm’s proprietary SPARC technology operates within a quickly evolving ecosystem.

Canada’s new Defense industrial strategy represents a generational pivot in national defense procurement. Supported by $81.8 billion in 2025 budget commitments and backed by $180 billion in procurement, as well as $290 billion in defense-related financing opportunities over the next decade, the strategy prioritizes Canadian digital technologies, innovation, and sovereign intellectual property. Autonomous systems, artificial intelligence, aerospace, and advanced sensing are clearly identified as high-value opportunities (ibn.fm/5KHJK).

The shift in policy underscores a wider global trend. Countries are tilting towards a domestically controlled, tech-driven system that can be quickly deployed and adaptable. Modern battlefields are increasingly reliant on real-time intelligence, autonomous platforms, and precision targeting powered by software rather than just hardware-based systems.

Sparc AI’s patented Spatial Predictive Approximation and Radial Convolution technology transforms standard cameras, sensors, and smart devices into precise coordinate acquisition systems. By transforming fixed, airborne, or mobile imaging platforms into intelligent targeting systems, the company enables precision location data without needing sophisticated military hardware. Sparc AI’s Target Acquisition System software platform and autonomous flight module further increase its usability across unmanned aerial systems and surveillance platforms.

In February 2026, the company announced an upgrade to Overwatch, its flagship GPS denied navigation product. Users can now leverage Overwatch’s corrected waypoints, mission plans, and positions and have them exported into the flight software they already use, thereby increasing Overwatch’s use case across defense and commercial fleets (ibn.fm/dN4ER).

As Canada invests in scaling domestic defense innovation and streamlining procurement through its newly created Defense Investment Agency, companies providing practical software-defined solutions may find increased alignment with procurement priorities. Drone innovation hubs, artificial intelligence-driven targeting, and autonomous control of defense-related intellectual property are integral components of the strategy, areas at the core of Sparc AI’s capabilities.

Beyond Canada, NATO countries are boosting their defense budgets to tackle rising security threats. Across the nations, spending targets exceed 2% of the total gross domestic product, implying that demand for advanced digital defense solutions is expected to grow steadily over the next decade. With software-based targeting and autonomous systems, countries and industries are better positioned for cost-efficient force multiplication, offering fiscal discipline and capability.

As governments pay greater attention to economic resilience, national security, and technological independence, AI-driven defense platforms are poised to gain greater relevance. Sparc AI’s proprietary technology and commercialization focus align with the rapidly changing procurement landscape, positioning the company to leverage the evolving defense infrastructure landscape.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

• The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells
• LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents
• The company is advancing LB-100 through clinical development in collaboration with academic and research institutions

Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to the immune system. Researchers are increasingly focused on strategies that make tumors more visible and susceptible to immune attack, and LIXTE Biotechnology Holdings (NASDAQ: LIXT) is developing a compound designed to contribute to that effort. Its lead candidate, LB-100, targets a cellular enzyme involved in tumor biology and immune regulation, with the goal of enhancing responsiveness to existing cancer therapies.

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells. Drugs targeting immune checkpoints such as PD-1 and PD-L1 have delivered durable responses in melanoma, lung cancer and other malignancies. According to the National Cancer Institute, immune checkpoint inhibitors work by blocking proteins that prevent T cells from attacking cancer cells, thereby restoring immune activity against tumors. Yet many tumors do not generate sufficient immune recognition signals, which limits the effectiveness of these treatments. Some cancers are characterized by low levels of tumor neoantigens, reduced T-cell infiltration or immunosuppressive tumor microenvironments, making them resistant to immunotherapy.

CAR-T cell therapy represents another major advance, particularly in certain hematologic malignancies. CAR-T therapy involves engineering a patient’s own T cells to better recognize and attack cancer. While effective in specific settings, CAR-T has shown more limited success in many solid tumors, in part because those tumors may evade immune detection or suppress immune cell activity within the tumor microenvironment.

As a result, oncology researchers are increasingly investigating agents that modify tumor immunogenicity. The idea is to alter tumor biology so that malignant cells produce stronger immune signals, recruit more T cells and become more susceptible to checkpoint inhibitors or cell-based therapies. A growing body of scientific literature supports the concept that increasing tumor neoantigen presentation and improving T-cell activation can enhance immunotherapy outcomes. Studies have shown that tumor mutation burden, neoantigen load and increased CD8+ T-cell infiltration correlate with improved response rates to immune checkpoint inhibitors, highlighting the importance of tumor immunogenicity in determining treatment outcomes. 

LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents. LB-100 is a small-molecule inhibitor of protein phosphatase 2A, or PP2A, an enzyme that plays a role in cell cycle regulation, DNA damage response and immune signaling pathways. According to LIXTE, PP2A inhibition has been shown in preclinical studies to enhance neo-antigen production and increase T-cell proliferation, potentially converting tumors that are nonresponsive to immunotherapy into ones that are more responsive. By inhibiting PP2A, LB-100 may alter the tumor microenvironment in ways that promote immune recognition and enhance the effects of checkpoint inhibitors or other immune-based therapies.

LIXTE describes LB-100 as a first-in-class compound designed to enhance the effectiveness of standard anti-cancer treatments, including chemotherapy, radiation and immunotherapy. The company’s scientific rationale is based on research demonstrating that PP2A regulates pathways involved in tumor cell survival and immune evasion. Preclinical studies suggest that inhibiting PP2A can increase tumor cell susceptibility to immune attack while also promoting T-cell activity, aligning with the broader scientific interest in boosting tumor immunogenicity.

The company is advancing LB-100 through clinical development in collaboration with academic and research institutions. LB-100 has been evaluated in early-phase clinical trials in patients with advanced solid tumors and other malignancies, both as a monotherapy and in combination regimens. These studies are designed to assess safety, tolerability and preliminary signals of efficacy, particularly in settings where tumors have demonstrated resistance to existing therapies.

Beyond its scientific platform, LIXTE’s development model includes partnerships with research institutions and continued exploration of PP2A inhibition across multiple tumor types. The company has stated that LB-100’s mechanism may have applicability in a variety of solid tumors, reflecting the widespread challenge of immunotherapy resistance. By focusing on the biological processes that limit immune recognition, LIXTE aims to address one of oncology’s most pressing unmet needs.

As immunotherapy continues to reshape cancer treatment, the next frontier may lie not only in discovering new immune agents, but in making resistant tumors visible and vulnerable to the immune system. Agents that enhance tumor immunogenicity could play a pivotal role in expanding the number of patients who benefit from immune-based therapies. Through the development of LB-100 and its focus on PP2A inhibition, LIXTE Biotechnology Holdings is positioning itself within this important and evolving area of cancer research, seeking to help turn immunologically “cold” tumors into ones that can be effectively targeted by the body’s own defenses.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

• Beeline Holdings operates a fully digital mortgage and title platform built around AI and automation, with core tools such as AI chatbot Bob and workflow engine Hive designed to shorten mortgage closing timelines.
• The company targets both primary home buyers and real estate investors, with a focus on younger borrowers and equity-rich homeowners, emphasizing self-service access to rates, approvals, and documentation, available online at all times.
• Management has outlined plans to further scale transaction volume and software-based offerings in 2026.

Beeline Holdings (NASDAQ: BLNE), a rapidly growing digital mortgage platform company redefining the path to homeownership, operates at the intersection of mortgage lending, title services, and financial technology, offering a digital-first alternative to a process that has historically been paper-heavy and time-consuming. Through its wholly owned subsidiary, Beeline Loans Inc., the company provides mortgage products designed to be originated, processed, and closed largely online.

The company describes itself as a technology-forward mortgage and title platform that uses artificial intelligence and automation to simplify access to home financing. Its stated objective is to reduce friction across the mortgage lifecycle, from rate discovery and pre-approval to underwriting and closing, while lowering costs and shortening timelines.

At the core of Beeline’s platform is “Bob,” an AI-powered mortgage chatbot that interacts directly with borrowers. Available 24/7, Bob is designed to provide rate quotes, answer questions, and guide users through the early stages of the mortgage process. According to the company, Bob has demonstrated that it delivers near-real-time eligibility assessments, offering borrowers a high level of confidence about qualification within minutes rather than days.

Supporting customer-facing automation is Beeline’s internal production engine, Hive. Hive replaces manual workflows with task-based automation across underwriting, processing, title coordination, and closing. The company says this system has reduced average closing times to between 14 and 21 days, compared with industry norms that often exceed a full month.

Another component of the platform is BlinkQC, an AI-driven quality control tool developed by Beeline to replace third-party loan review services. By automating compliance checks internally, the company aims to reduce costs and streamline post-closing processes.

In addition, Beeline operates a dedicated title services unit, Beeline Title, which supports digital collateral transfer and remote closings. Title services are integrated into the broader lending workflow, allowing borrowers and investors to complete transactions without relying on separate vendors. Management has emphasized that tighter integration between lending and title functions is intended to reduce delays and improve transparency.

The company’s product set is aimed at two primary customer segments, younger buyers looking for a personal home, and buyers looking for home investment properties. 

Younger buyers, particularly millennials and gig-economy workers, often face challenges in meeting traditional underwriting criteria. According to data cited by National Mortgage Professional, only 54.9% of millennials and 26.1% of Gen Z owned homes in 2024, with limited access to mortgages cited as a key constraint (https://ibn.fm/hOVfx). Beeline’s platform is built to address that gap by using alternative data and AI-driven assessments to evaluate eligibility more quickly. The goal, management says, is not to loosen standards, but to make decisions faster and more transparent for borrowers who may have non-traditional income profiles.

A second major segment is real estate investors. A significant portion of Beeline’s lending activity supports buyers of investment properties, including short-term rental operators. The company offers products such as debt service coverage ratio (“DSCR”) loans and bank statement loans, which are commonly used by investors whose income does not fit standard wage-based models.

In addition to mortgages, Beeline has introduced BeelineEquity, a blockchain-enabled fractional home equity product. The offering allows homeowners to access liquidity without taking on traditional debt and is currently focused on higher-value ZIP codes where equity levels are substantial. Management reported that initial transactions were completed in 2025, with a pipeline extending into 2026.

From a financial standpoint, Beeline reported  quarterly double digit revenue growth in 2025.  The company ended the year with more than $50 million in total equity and no long-term debt, excluding warehouse credit lines used to fund loan originations. During the year, Beeline expanded its warehouse lending capacity to $25 million, supporting higher origination volume.

Looking ahead, management has outlined priorities centered on scaling transaction activity across its mortgage, title, and equity platforms. Liuzza pointed to improving mortgage market conditions and policy actions aimed at supporting housing liquidity, while stopping short of offering forecasts tied to rate movements.

Operationally, Beeline plans to continue expanding its use of AI across back-office functions, with the stated aim of increasing volume without a proportional rise in headcount or fixed costs. 

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE